Prevention of gastric cancer

Chinese Journal of Digestive Diseases

Volumn 4, Issue 3, 2003, Pages 100-104

  Chan, Annie On On ^a   Wong, Wai Man ^a   Lam, Shiu Kum ^a   Wong, Benjamin Chun Yu ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIINFECTIVE AGENT; ANTIOXIDANT; ASCORBIC ACID; ASTAXANTHIN; BETA CAROTENE; CAROTENOID; CHINESE DRUG; CYCLOOXYGENASE 2 INHIBITOR; FLAVONOID; FOLIC ACID; GARLIC EXTRACT; GREEN TEA EXTRACT; HERBACEOUS AGENT; INDOMETACIN; LIPOXYGENASE INHIBITOR; MOLYBDENUM; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; POLYPHENOL; RETINOL; RIBOFLAVIN; SELENIUM; SULINDAC; ZINC;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ATROPHIC GASTRITIS; CANCER MORTALITY; CANCER RISK; CHEMOPROPHYLAXIS; CHRONIC DISEASE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DYSPLASIA; GASTROINTESTINAL DISEASE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTESTINE METAPLASIA; NONHUMAN; PRECANCER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STOMACH CANCER;

EID: 0344465003     PISSN: 14439611     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1443-9573.2003.00128.x     Document Type: Review

References (57)

1. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965; 64: 31-49.
2. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process (First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention). Cancer Res 1992; 52: 6735-40.
3. Wong BCY, Lam SK. Diet and gastric cancer. GI Cancer 1999; 3: 1-10.
4. Xiao SD, Meng XJ, Shi Y, Hu YB, Zhu SS, Wang CW. Interventional study of high dose folic acid in gastric carcinogenesis in beagles, Gut 2002; 50: 61-4.
5. Yu GP, Hsieh CC, Wang LY, Yu SZ, Li XL, Jin TH. Green-tea consumption and risk of stomach cancer: a population-based case-control study in Shanghai. Cancer Causes Control 1995; 6: 532-8.
6. Yu GP, Hsieh CC. Risk factors for stomach cancer: a population-based case-control study in Shanghai. Cancer Causes Control 1991; 2: 169-74.
7. Kono S, Ikeda M, Tokudome S, Kuratsune M. A case-control study of gastric cancer and diet in northern Kyushu, Japan. Jpn J Cancer Res 1988; 79: 1067-74.
8. Inoue M, Tajima K, Hirose K et al. Tea and coffee consumption and the risk of digestive tract cancers: data from a comparative case-referent study in Japan. Cancer Causes Control 1998; 9: 209-16.
9. Ji BT, Chow WH, Yang G et al. The influence of cigarette smoking, alcohol, and green tea consumption on the risk of carcinoma of the cardia and distal stomach in Shanghai. Cancer 1996; 77: 2449-57.
10. Tajima K, Tominaga S. Dietary habits and gastro-intestinal cancer: a comparative case-control study of stomach and large intestinal cancers in Nagoya, Japan. Jpn J Cancer Res 1985; 76: 705-16.
11. Lee HH, Wu HY, Chuang YC et al. Epidemiologic characteristics and multiple risk factors of stomach cancer in Taiwan. Anticancer Res 1990; 10: 875-81.
12. Tsubono Y, Nishino Y, Komatsu S et al. Green tea and the risk of gastric cancer in Japan. N Engl J Med 2001; 344: 632-6.
13. Blot WJ, Li J-Y, Taylor PR et al. Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence and disease specific mortality in the general population. J Natl Cancer Inst 1993; 85: 1483-92.
14. Tsubono Y, Tsugane S, Gey KF. Plasma antioxidant vitamins and carotenoids in five Japanese populations with varied mortality from gastric cancer. Nutr Cancer 1999; 34: 56-61.
15. Garcia-Closas R, Gonzalez CA, Agudo A et al. intake of specific carotenoids and flavonoids and the risk of gastric cancer in Spain. Cancer Causes Control 1999; 10: 71-5.
16. Palli D, Russo A, Saieva C, Salvini S, Amorosi A, Decarli A. Dietary and familial determinants of 10-year survival among patients with gastric carcinoma. Cancer 2000; 89: 1205-13.
17. The Alpha-tocopherol Beta-carotene Cancer Prevention Study Group. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-35.
18. Hennekens CH, Buring JE, Manson JE et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145-9.
19. Akre K, Ekstrom AM, Signorello LB et al. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br J Cancer 2001; 84: 965-8.
20. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322-7.
21. Gridley G, McLaughlin JK, Ekbom A et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85: 307-11.
22. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978; 31: 691-6.
23. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effects of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993; 14: 1493-7.
24. Rubio CA. Antitumoral activity of indomethacin in experimental esophageal tumors. J Natl Cancer Inst 1984; 72: 705-7.
25. Coogan PF, Rosenberg L, Palmer JR, et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomark Prev 2000; 9: 119-23.
26. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000; 320: 1642-6.
27. 1 isoenzyme suppresses indomethacin-induced apoptosis in gastric epithelial cells. Gastroenterology 2000; 118: 507-14.
28. Jiang XH, Lam SK, Lin MCM et al. Novel target for induction of apoptosis by cyclooxygenase-2 inhibitor through a protein kinase C-beta 1-dependent pathway. Oncogene 2002; 21: 6113-22.
29. Wong BCY, Jiang XH, Fan XM et al. Suppression of RelA/p65 nuclear translocation independent of I kappa B-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer. Oncogene 2003; 22: 1189-97.
30. Wu J, Xia HHX, Tu SP et al. 15-lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer. Carcinogenesis 2003; 24: 243-7.
31. Wong BCY, Wang WP, Lin MCM et al. 12-lipoxygenase inhibition induced apoptosis in human gastric cancer cells. Carcinogenesis 2001; 22: 1349-54.
32. Forman D, Newell DG, Fullerton F et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ 1991; 302: 1302-5.
33. Forman D, Webb P, Parsonnet J. H. pylori and gastric cancer [Letter]. Lancet 1994; 343: 243-4.
34. Parsonnet J, Friedman GD, Vandersteen DP et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-31.
35. Talley NJ, Zinsmeister AR, Weaver A et al. Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst 1991; 83: 1734-9.
36. Sipponen P, Kosunen TU, Valle J, Riihela M, Seppala K. Helicobacter pylori infection and chronic gastritis in gastric cancer. J Clin Pathol 1992; 45: 319-23.
37. Kang HC, Chung IS. Helicobacter pylori infection and gastric adenocarcinoma in Korea: prevalence and distribution of Helicobacter pylori in resected specimen of gastric cancer. Korea Cathol Med Coll 1992; 45: 849-62.
38. Hansson L, Engstrand L, Nvren O et al. Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma. Gastroenterology 1993; 105: 1098-103.
39. Blaser MJ, Kobayashi K, Cover TL, Cao P, Feurer ID, Perez-Perez GI. Helicobacter pylori infection in Japanese patients with adenocarcinoma of the stomach. Int J Cancer 1993; 55: 799-802.
40. Lin JT, Wang JT, Wang TH, Wu MS, Lee TK, Chen CJ. Helicobacter pylori infection in a randomly selected population, healthy volunteers, and patients with gastric ulcer and gastric adenocarcinoma: A seroprevalence study in Taiwan. Scand J Gastroenterol 1993; 28: 1067--72.
41. Kuipers EJ, Gracia-Casanova M, Pena AS et al. Helicobacter pylori serology in patients with gastric carcinoma. Scand J Gastroenterol 1993; 28: 433-7.
42. Estevens J, Fidalgo P, Tendeiro T et al. Anti-Helicobacter pylori antibodies prevalence and gastric adenocarcinoma in Portugal: report of a case-control study. Eur J Cancer Prev 1993; 2: 377-80.
43. Archimandritis A, Bitsikas J, Tjivras M et al. Non-cardia gastric adenocarcinoma and Helicobacter pylori infection. Int J Gastroenterol 1993; 25: 368-71.
44. Correa P, Fox J, Fontham E et al. Helicobacter pylori and gastric carcinoma: Serum antibody prevalence in Populations with contrasting cancer risks. Cancer 1990; 66: 2569-74.
45. Sierra R, Munoz N, Pena AS et al. Antibodies to Helicobacter pylori and pepsinogen levels in children from Costa Rica: comparison of two areas with different risks for stomach cancer. Cancer Epidemiol Biomarkers Prev 1992; 1: 449-54.
46. Buiatti E, Palli D, Amadori D et al. Methodological issues in a multicentric study of gastric cancer and diet in Italy: study design, data sources and quality controls. Tumori 1989; 75: 410-19.
47. Palli D, Decarli A, Cipriani F et al. Helicobacter pylori antibodies in areas of Italy at varying gastric cancer risk. Cancer Epidemiol Biomarkers Prev 1993; 2: 37-40.
48. Lin HZ, Zhang YC, Zhang WF, Bai XW. Campylobacter pyloridis (Cp) infection of gastric mucosa in the high and low risk areas ot gastric cancer in Liaoning province. Chung Hua Chung Liu Tsa Chih 1989; 11: 365-7.
49. Wong BC, Lam SK, Ching CK et al. Differential Helicobacter pylori infection rates in two contrasting gastric cancer risk regions of South China: China Gastric Cancer Study Group. J Gastroenterol Hepatol 1999; 14: 120-5.
50. Tsugane S, Kabuto M, Imai H et al. Helicobacter pylori, dietary factors, and atrophic gastritis in five Japanese populations with different gastric cancer mortality. Cancer Causes Control 1993; 4: 297-305.
51. Forman D, Sitas F, Newell DG et al. Geographic association of Helicobacter pylori antibody prevalence and gastric cancer mortality in rural China. Int J Cancer 1990; 46: 608-11.
52. The EUROGAST Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993; 341: 1359-62.
53. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
54. Correa P, Fontham ET, Bravo JC et al. Chemoprevention of gastric dysplasia: Randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000; 92: 1881-8.
55. Gail MH, You WC, Chang YS et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Control Clin Trials 1998; 19: 352-69.
56. Sung JJY, Lin S-R, Ching JYL et al. Atrophy and intestinal metaplasia one year after cure of Helicobacter pylori infection: a prospective randomized study. Gastroenterology 2000; 119: 7-14.
57. Guo HQ, Guan P, Shi HL, Zhang X, Zhou BS, Yuan Y. Prospective cohort study of comprehensive prevention to gastric cancer. World J Gastroenterol 2003; 9: 432-6.